Effects of bupropion on cognitive performance during initial tobacco abstinence

Drug and Alcohol Dependence

Volumn 133, Issue 1, 2013, Pages 283-286

  Perkins, Kenneth A ^a   Karelitz, Joshua L ^a   Jao, Nancy C ^a   Gur, Ruben C ^b   Lerman, Caryn ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Attention; Bupropion; Cognition; Smoking cessation; Tobacco dependence; Working memory

Indexed keywords

AMFEBUTAMONE; PLACEBO;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXECUTIVE FUNCTION; FEMALE; HUMAN; MALE; MEMORY CONSOLIDATION; PRIORITY JOURNAL; RESPONSE TIME; SHORT COURSE THERAPY; SMOKING CESSATION; STIMULUS RESPONSE; TASK PERFORMANCE; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; WORKING MEMORY;

NICOTIANA TABACUM;

ATTENTION; BUPROPION; COGNITION; SMOKING CESSATION; TOBACCO DEPENDENCE; WORKING MEMORY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ATTENTION; BUPROPION; COGNITION DISORDERS; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; REACTION TIME; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84884415806     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.05.003     Document Type: Article

References (21)

1. Acheson A., de Wit H. Bupropion improves attention but does not affect impulsive behavior in healthy young adults. Exp. Clin. Psychopharmacol. 2008, 16:113-123.
2. Ashare R.L., Ray R., Lerman C., Strasser A.A. Cognitive effects of the acetylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: a pilot feasibility study. Drug Alcohol Depend. 2012, 126:263-267.
3. Cinciripini P.M., Robinson J.D., Karam-Hage M., Minnix J.A., Lam C., Versace F., Brown V.L., Engelmann J.M., Wetter D.W. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry 2013, 70:522-533.
4. Cohen J. Statistical Power Analysis for the Behavior Sciences 1988, Lawrence Erlbaum Associates, Inc., Hillsdale, NJ. 2nd ed.
5. Gur R.C., Richard J., Hughett P., Calkins M.E., Macy L., Bilker W.B., Brensinger C., Gur R.E. A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation. J. Neurosci. Methods 2010, 187:254-262.
6. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.-O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 1991, 86:1119-1127.
7. Hughes J.R., Hatsukami D.K. Instructions for Use of the Minnesota Withdrawal Scale-Revised 2007, Retrieved from www/uvm.edu/~hbpl.
8. Hughes J.R., Solomon L.J., Fingar J.R., Naud S., Helzer J.E., Callas P.W. The natural history of efforts to stop smoking: a prospective cohort study. Drug Alcohol Depend. 2013, 128:171-174.
9. Jacobsen L.K., Krystal J.H., Mencl W.E., Westerveld M., Frost S.J., Pugh K.R. Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biol. Psychiatry 2005, 57:56-66.
10. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., Smith S.S., Muramoto M.L., Daughton D.M., Doan K., Fiore M.C., Baker T.B. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 1999, 340:685-691.
11. Kurtz M.M., Ragland J.D., Bilker W., Gur R.C., Gur R.E. Comparison of the continuous performance test with and without working memory demands in healthy controls and patients with schizophrenia. Schizophr. Res. 2001, 48:307-316.
12. Lerman C., Roth D., Kaufmann V., Audrain J., Hawk L., Liu A., Niaura R., Epstein L. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 2002, 67:219-223.
13. Loughead J., Ray R., Wileyto E.P., Ruparel K., Sanborn P., Siegel S., Gur R.C., Lerman C. Effects of the α4β2 partial agonist Varenicline on brain activity and working memory in abstinent smokers. Biol. Psychiatry 2010, 67:715-721.
14. Myers C.S., Taylor R., Moolchan E., Heishman S. Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray. Neuropsychopharmacology 2008, 33:588-598.
15. Patterson F., Jepson C., Strasser A.A., Loughead J., Perkins K.A., Gur R.C., Frey J.M., Siegel S., Lerman C. Varenicline improves mood and cognition during smoking abstinence. Biol. Psychiatry 2009, 65:144-149.
16. Patterson F., Jepson C., Loughead J., Perkins K., Strasser A.A., Siegel S., Frey J., Gur R., Lerman C. Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend. 2010, 106:61-64.
17. Perkins K.A., Lerman C., Fonte C., Mercincavage M., Stitzer M.L., Chengappa K.R.N., Jain A. Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clin. Pharmacol. Ther. 2010, 88:109-114.
18. Powell J., Dawkins L., West R., Pickering A. Relapse to smoking during unaided cessation: clinical, cognitive and motivational predictors. Psychopharmacology 2010, 212:537-549.
19. Ragland J.D., Turetsky B.I., Gur R.C., Gunning-Dixon F., Turner T., Schroeder L., Chan R., Gur R.E. Working memory for complex figures: an fMRI comparison of letter and fractal n-back tasks. Neuropsychology 2002, 16:370-379.
20. Schnoll R.A., Wileyto E.P., Pinto A., Leone F., Gariti P., Siegel S., Perkins K.A., Dackis C., Heitjan D.F., Berrettini W., Lerman C. A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend. 2008, 98:86-93.
21. Xu J., Mendrek A., Cohen M.S., Monterosso J., Rodriguez P., Simon S.L., Brody A., Jarvik M., Domier C.P., Olmstead R., Ernst M., London E.D. Brain activity in cigarette smokers performing a working memory task: effect of smoking abstinence. Biol. Psychiatry 2005, 58:143-150.